The purpose of the present study is to the clinical efficacy of basic fibroblast growth factors (bFGF) in coronary angiogenesis in the setting of chronic myocardial ischemia. Ischemic coronary disease is the leading cause of morbidity and mortality in the Western world. Most available therapeutic approaches aim either at relieving symptoms by reducing myocardial oxygen demand, preventing further disease progression by modifying risk factors, restoring flow to a localized segment of the arterial tree (angioplasty) or bypassing obstruction (bypass surgery). However, no attempts have been made to restore blood supply to the myocardium by providing new venues for blood flow. Therapeutic angiogenesis may serve this goal. Angiogenesis is a complex process involving endothelial and smooth muscle cell proliferation and migration, formation of new capillaries, breakdown of existing extracellular matrix and formation of a new one. Relatively little is know regarding physiological importance and therapeutic potential of this process in chronic myocardial ischemia and molecular cellular events involved in its regulation are poorly understood. Preliminary investigation using animal models have shown that bFGF can be used to stimulate physiologically significant angiogenesis in myocardial ischemia. However, to date there has been no experience with the use of this growth factor in patients. The present study, therefore, will examine 3 Specific Aims: I. Angiogenic efficiency of bFGF chronic myocardial ischemia; II. Role of magnetic resonance imaging in noninvasive assessment of coronary angiogenesis; III. valuation of other tyrosine kinase ligands in stimulation of angiogenesis in chronic myocardial ischemia.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
1P50HL056993-02
Application #
6273245
Study Section
Project Start
1998-04-01
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Raj, Satish R; Robertson, David; Biaggioni, Italo et al. (2007) Abnormal valsalva maneuver is not always a sign of congestive heart failure. Am J Med 120:e15-6
Laham, Roger J; Simons, Michael; Pearlman, Justin D et al. (2002) Magnetic resonance imaging demonstrates improved regional systolic wall motion and thickening and myocardial perfusion of myocardial territories treated by laser myocardial revascularization. J Am Coll Cardiol 39:1-8
Ruel, Marc; Laham, Roger J; Parker, J Anthony et al. (2002) Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 124:28-34
Post, Mark J; Laham, Roger J; Kuntz, Richard E et al. (2002) The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis. Clin Cardiol 25:271-8
Pearlman, Justin D; Laham, Roger J; Post, Mark et al. (2002) Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr Pharm Des 8:1467-96
Pearlman, J D; Gertz, Z M; Wu, Y et al. (2001) Serial motion assessment by reference tracking (SMART): application to detection of local functional impact of chronic myocardial ischemia. J Comput Assist Tomogr 25:558-62
Laham, R J; Simons, M; Sellke, F (2001) Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med 52:485-502
Hoffmeister, K M; Falet, H; Toker, A et al. (2001) Mechanisms of cold-induced platelet actin assembly. J Biol Chem 276:24751-9
Sato, K; Wu, T; Laham, R J et al. (2001) Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 37:616-23
Tonks, N K; Neel, B G (2001) Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 13:182-95

Showing the most recent 10 out of 31 publications